Mr. Ron Nagar reports

TEMPRAMED ENTERS STRATEGIC MEDIA PARTNERSHIP WITH DR. PHIL'S ENVOY MEDIA, VALIDATING PRODUCT PORTFOLIO AND ACCELERATING MARKET ADOPTION ACROSS THE UNITED STATES

Tempramed Technologies Ltd. has entered into a strategic media partnership with Dr. Phil and Envoy Media, providing access to an audience of over 19 million monthly viewers, which marks a significant step in accelerating market adoption and brand authority across the United States.

Partnership highlights:

• Exclusive title sponsorship of a Dr. Phil television special focused on prescription medication safety;
• Tempramed positioned as the featured solution within the program narrative, with no competing brands;
• Multiplatform distribution across broadcast TV, podcasts, YouTube and social media with millions of expected viewers;
• Full content usage rights enable long-term monetization across paid media, digital acquisition and B2B (business-to-business) outreach;
• Campaign supports Tempramed's transition from awareness building to scaled demand generation and enterprise engagement.

"Dr. Phil brings unmatched credibility and reach to conversations that matter deeply to patients and families," said Ron Nagar, chief executive officer of Tempramed. "This partnership allows us to educate millions of people about a largely overlooked risk in medication use -- temperature exposure -- while positioning Tempramed as the clear, trusted solution for medication storage and management. For our investors, this is about accelerating awareness, demand and enterprise engagement at national scale."

Under the agreement, Tempramed will serve as the exclusive title sponsor of a full-length, 44-minute Dr. Phil-hosted television special focused on common and often dangerous mistakes people make with prescription medications. The program is scheduled to air as a Dr. Phil Envoy TV special in May, 2026.

The special will devote airtime to Tempramed's technology, education around medication temperature safety, and real-world use cases. The segment includes an on-air interview with a Tempramed spokesperson, integrated calls to action and persistent on-screen branding.

Dr. Phil remains one of the most trusted voices in American media, reaching approximately 19 million monthly viewers across broadcast and digital platforms, with a social following exceeding 25 million users. Tempramed's placement within an editorial, non-infomercial format positions the company as a trusted authority rather than an advertiser.

The campaign includes multiplatform distribution across broadcast TV, podcasts, YouTube and social media, along with cut-down versions and short-form content. Tempramed receives full usage rights to repurpose the content across digital acquisition, enterprise sales, payer engagement and international expansion initiatives.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered (U.S. Food and Drug Administration), space-grade thermal insulation devices that work 24 hours a day/seven days a week without batteries or external power. With a proven product line, including Vivi Cap and Vivi Epi, and a smart technology platform on the horizon, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed is advancing the future of medication protection and adherence.

We seek Safe Harbor.